A 72-year-old female patient presented with an end-stage renal disease on on-line hemodiafiltration and warfarin therapy with advanced ulcerated calciphylaxis on the lower extremities, complicated by two episodes of cellulitis. She was successfully treated for 8 months with intravenous sodium thiosulfate in combination with modification of medication and dialysis treatment, careful wound care, and other supportive measures. Calciphylaxis is an uncommon life-threatening systemic disease, mostly occurring in patients with chronic kidney disease and other risk factors. Vascular calcifications and inflammation lead to thrombotic occlusions of the cutaneous and subcutaneous arterioles, which provoke livedoid painful plaques with possible progression to necrotic ulcers. Conventional treatment is supportive. In recent decades, off-label treatment with sodium thiosulfate, a potent calcium chelator, antioxidant, and vasodilator, has been increasingly reported to be highly efficient in calciphylaxis, leading to significantly lower mortality rates. Knowledge of advancement in the treatment of calciphylaxis, which was previously a highly fatal disease, is important for physicians and other professionals from various medical fields.

Download full-text PDF

Source

Publication Analysis

Top Keywords

sodium thiosulfate
12
intravenous sodium
8
calciphylaxis
5
successful treatment
4
treatment extensive
4
extensive uremic
4
uremic calciphylaxis
4
calciphylaxis intravenous
4
thiosulfate potential
4
potential treating
4

Similar Publications

The cardiovascular risks linked to PM include calcification in both vasculature and myocardial tissues, leading to structural changes and functional decline. Through the selection of a clinically proven endogenous agent, sodium thiosulfate (STS), capable of addressing PM related cardiac abnormalities, we not only address the absence of effective solutions to mitigate PM toxicity, but also provide evidence for the repurposing potential of STS in ameliorating PM induced cardiac damage. Female Wistar rats were exposed to PM (250 μg/m) for 3 h daily for 21 days.

View Article and Find Full Text PDF

Calciphylaxis is a rare and serious disorder characterized by vascular calcification and occlusion of the microvessels in the dermis, subcutaneous adipose tissue, visceral organs, and musculature. Studies have suggested that the major risk factors for developing calciphylaxis are chronic kidney disease and secondary hyperparathyroidism. Its diagnosis is clinical, and the treatment includes a multidisciplinary approach, although there are no clinical protocols based on randomized clinical trials.

View Article and Find Full Text PDF

Managing Calciphylaxis: Insights from Real-World Cases at a Tertiary Academic Center.

Adv Skin Wound Care

January 2025

At University of Michigan Medical School, Ann Arbor, Michigan, United States, Kanika Kochhar, DPM, is Podiatry Fellow; and Brennen O'Dell, DPM, Garneisha Torrence, DPM, MHMS, and Alton Johnson, DPM, DABPM, FACPM, FASPS, CWSP, are Clinical Assistant Professors. Carey Spitler, MSN, NP-C, CWON, is Nurse Practitioner, University of Michigan Health, Michigan Medicine, Ann Arbor. Also at University of Michigan Medical School, Brian Schmidt, DPM, is Clinical Associate Professor.

Calciphylaxis is a rare and potentially fatal condition involving chronic, nonhealing wounds caused by microvascular calcification. There is currently no approved treatment for calciphylaxis, contributing to its devastating impacts on quality of life. In this case series, the authors highlight instances of potentially misdiagnosed calciphylaxis in a cohort of patients and emphasize the importance of accurate diagnosis through multidisciplinary management approaches.

View Article and Find Full Text PDF

Clinical efficacy and safety of sodium thiosulfate in the treatment of uremic pruritus: a meta-analysis of randomized controlled trials.

Arch Dermatol Res

January 2025

Blood Purification Center, Zhejiang Hospital, 1229 Gudun Road, Xihu District, Hangzhou, Zhejiang, 310030, China.

Uremic pruritus (UP) is a debilitating condition frequently associated with chronic kidney disease, severely impairing patients' quality of life and contributing to increased mortality. Recent studies have suggested that intravenous sodium thiosulfate (STS) may offer therapeutic relief for pruritus in patients undergoing hemodialysis. To assess its effectiveness, we conducted a systematic review and meta-analysis to explore the potential of intravenous STS in managing UP.

View Article and Find Full Text PDF

Chemoprotective Mechanism of Sodium Thiosulfate Against Cisplatin-Induced Nephrotoxicity Is via Renal Hydrogen Sulfide, Arginine/cAMP and NO/cGMP Signaling Pathways.

Int J Mol Sci

January 2025

Department of Animal Experimentation, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra P.O. Box LG581, Ghana.

Cisplatin is a common and highly effective chemotherapeutic agent whose nephrotoxic side effect is well-characterized. Sodium thiosulfate (STS), an FDA-approved hydrogen sulfide (HS) donor drug, is emerging as a chemoprotective agent against cisplatin-induced nephrotoxicity (CIN). In this study, we investigated the chemoprotective mechanism of STS in a rat model of CIN.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!